Updated:
TriSalus Life Sciences
Mary Szela's TriSalus Life Sciences combines an FDA-cleared drug-delivery device with a proprietary immunotherapy pipeline to treat liver and pancreatic...
TriSalus Life Sciences
TriSalus Life Sciences, headquartered in Westminster, Colorado, operates at the intersection of medical device innovation and immuno-oncology drug development. The company pursues a singular therapeutic focus: overcoming the biological barriers that prevent effective treatment of solid tumors in the liver and pancreas. Its foundational premise is that current systemic and local therapies are often defeated by the high-pressure tumor microenvironment, which limits drug penetration and suppresses immune response. The company's model integrates two interdependent pillars. Its Pressure-Enabled Drug Delivery (PEDD) technology, commercialized as the TriNav Infusion System, is an FDA-cleared device designed to overcome intratumoral pressure to deliver therapeutics more effectively to targeted lesions. The second pillar is the company's investigational immunotherapeutic candidate, nelitolimod (SD-101), a Toll-like receptor 9 (TLR9) agonist that is administered via the TriNav system. This combination strategy targets the dual challenges of drug delivery and immune activation. Clinical programs include the Phase 2 PERIO-02 trial evaluating the combination in uveal melanoma liver metastases, and the DELIVER study in hepatocellular carcinoma and intrahepatic cholangiocarcinoma (per the firm's investor communications). The company was co-founded by CEO Mary Szela and the physician-inventors of the PEDD technology. In 2021, TriSalus completed a business combination with MedTech Acquisition Corporation, a special purpose acquisition company, to become publicly listed on the Nasdaq (per the firm's S-1 filings, 2021). The organization currently operates a direct commercial sales force that markets the TriNav system to interventional radiologists across the United States, generating product revenue as it simultaneously funds its drug-development pipeline. As of its most recent quarterly filing in 2024, the company has reported the active enrollment of patients in multiple clinical-stage programs. The structural differentiator in TriSalus is its device-to-drug economic flywheel. Unlike a standalone pharmaceutical company that funds long, cash-burning development cycles entirely from capital markets, TriSalus generates recurring commercial revenue from a proprietary delivery device already in clinical use. This device simultaneously serves as the exclusive delivery platform for its own pipeline of investigational drugs, creating a closed-loop system where commercial traction directly informs and finances clinical advancement.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Westminster
Corporate office
Westminster, CO, United States
Principals
Mary Szela
Chief Executive Officer
Bryan F. Cox
Chief Scientific Officer
James Alecxih
Chief Financial Officer
Sector focus
Frequently asked questions
What is TriSalus Life Sciences' core therapeutic strategy?
TriSalus targets the tumor microenvironment in the liver and pancreas, which are historically resistant to systemic and local therapies due to high intratumoral pressure. The strategy pairs the FDA-cleared Pressure-Enabled Drug Delivery (PEDD) system, which overcomes this pressure to deliver therapeutics, with the company's own investigational TLR9 agonist, nelitolimod. The goal is to improve both drug penetration and local immune activation.
How does the TriNav Infusion System generate revenue for the company?
The TriNav system is marketed directly to interventional radiologists in the United States through a dedicated commercial sales force. Revenue is generated from the sale of the single-use, disposable device each time it is used in a procedure. This product revenue is recognized currently and helps offset the research and development costs of the company's ongoing clinical-stage drug programs.
What clinical-stage assets is TriSalus currently developing?
TriSalus is developing nelitolimod (SD-101), an investigational immunotherapeutic, delivered through its TriNav system. The lead clinical program is the Phase 2 PERIO-02 trial, which is evaluating this combination in patients with uveal melanoma that has metastasized to the liver. A second program, DELIVER, is studying the approach in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
How did TriSalus Life Sciences go public?
TriSalus did not conduct a traditional initial public offering. In 2021, the company entered into a definitive business combination agreement with MedTech Acquisition Corporation, a publicly traded special purpose acquisition company (SPAC). Upon closing the transaction in 2021, the combined company was renamed TriSalus Life Sciences, Inc. and began trading on the Nasdaq under the ticker TLSI (per the firm's S-1 filings, 2021).
What makes the TriNav delivery device different from standard catheters?
Standard endovascular catheters deliver therapy into an arterial blood vessel without compensating for the elevated interstitial fluid pressure inside a solid tumor. The TriNav system modulates pressure and flow to overcome this barrier, enabling a documented improvement in the convective delivery of therapeutic agents into the targeted tumor tissue. It is currently cleared by the FDA for the infusion of physician-specified agents into the hepatic artery.
Who leads the clinical and commercial operations at TriSalus?
Mary Szela serves as Chief Executive Officer and co-founder, bringing experience from prior senior roles at AbbVie and AstraZeneca. Bryan F. Cox, Ph.D., is the Chief Scientific Officer, overseeing the drug and device R&D programs. The commercial team is structured as a direct sales force targeting interventional radiology practices across major U.S. metropolitan markets.
Does TriSalus operate exclusively in the United States?
Currently, all of TriSalus' commercial sales activity and clinical trial sites are based in the United States. The TriNav Infusion System is FDA-cleared for use in the U.S., and the company does not report any commercial distribution partnerships or clinical trial sites outside of the country at this time.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: